VNDA Stock Analysis: Buy, Sell, or Hold?
VNDA - Vanda Pharmaceuticals Inc.
$7.54
-0.24 (-3.08%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 12, 2026
11d
Get Alerted When VNDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
4 traders called VNDA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VNDA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: VNDA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: VNDA is currently trading at $7.54, which is considered fair relative to its 30-day fair value range of $7.15 to $8.13.
Technical Outlook: Technically, VNDA is in a strong uptrend. Immediate support is located at $7.14, while resistance sits at $8.27. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (1th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.62 (+75.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VNDA is in a strong uptrend. Immediate support is located at $7.14, while resistance sits at $8.27. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (1th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.62 (+75.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$7.15 -
$8.13
Company Quality Score
53/100
(HOLD)
Options IV Signal
1th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
75.8%
Protect Your Profits
Holding VNDA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 1th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 75.1% below Wall St target ($13.62)
- CAUTION: Recommendation downgraded due to -5.9% 5-day decline
Fair Price Analysis
30-Day Fair Range
$7.15 -
$8.13
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$0.89
(11.8%)
Support & Resistance Levels
Support Level
$7.14
Resistance Level
$8.27
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-5.37
Wall Street Target
$13.63
(+75.1%)
Revenue Growth (YoY)
18.1%
Earnings Growth (YoY)
-95.9%
Profit Margin
-39.7%
Last updated: January 30, 2026 7:48 PM ET
Data refreshes hourly during market hours. Next update: 8:48 PM
Data refreshes hourly during market hours. Next update: 8:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VNDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$22 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
Advanced VNDA Option Strategies
Professional options setups generated by AI based on today's VNDA price and gamma walls.
